2023-04-19 09:40:15 ET
- Biotricity ( NASDAQ: BTCY ) reached a record $12M annualized revenue run rate in March 2023.
- The company attributed its strengthening financials to the growing sales of its product line of remote cardiac monitors spanning consumers to cardiologists, the ramp up of its subscription-based recurring service revenues, and the early success of its recently expanded distribution strategy.
- "Our continued growth, at a time when many tech companies are downsizing, is a testament to our execution of our capital efficient business. It reflects the value-added resiliency of our cloud-based Biosphere solutions' excellent health and wellness cost/benefit -- as insurers already fully recognize," said Dr. Waqaas Al-Siddiq, Biotricity Founder and CEO.
For further details see:
Biotricity touches $12M in annualized revenue